Richard Scott Struthers - 02 Apr 2025 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
President & CEO, Director
Signature
Tobin Schilke, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
02 Apr 2025
Net transactions value
+$155,226
Form type
4
Filing time
04 Apr 2025, 16:30:05 UTC
Previous filing
21 Mar 2025
Next filing
16 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $155,226 +81,270 +25% $1.91 410,417 02 Apr 2025 Direct
holding CRNX Common Stock 570,805 02 Apr 2025 By Family Trust 1
holding CRNX Common Stock 110,000 02 Apr 2025 By Family Trust 2
holding CRNX Common Stock 110,000 02 Apr 2025 By Family Trust 3
holding CRNX Common Stock 100,000 02 Apr 2025 By Family Trust 4
holding CRNX Common Stock 1,000 02 Apr 2025 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (Right to Buy) Options Exercise $0 -81,270 -100% $0.000000 0 02 Apr 2025 Common Stock 81,270 $1.91 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.